All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
At the European Alliance of Associations for Rheumatology (EULAR) Congress 2024, our Steering Committee member Peter Nash, Griffith University, Queensland, AU, interviewed Kurt De Vlam, KU Leuven, Leuven, BE about his current work in psoriatic arthritis (PsA).
Pain mechanisms in psoriatic arthritis
De Vlam explains his research on metabolic profiling in PsA, particularly the role of lipids in disease initiation. He then focuses on his studies exploring different types of pain mechanisms in PsA, highlighting how a greater understanding of this might influence treatment selection. Finally, De Vlam discusses the role of Janus kinase (JAK) inhibitors in the treatment of PsA, especially in patients with higher pain levels.
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox